Greater than the sum of its parts: Artemisinins are currently in phase I-II clinical trials against breast, colorectal and non-small-cell lung cancers. In an attempt to offer increased specificity, a series of hybrid artemisinin-polypyrrole minor groove binder conjugates are described. DNA binding/modelling studies and preliminary biological evaluation give insights into their mechanism of action and the potential of this strategy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/cmdc.201200536 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!